Literature DB >> 7652765

The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.

V Palathumpat1, S Dejbakhsh-Jones, S Strober.   

Abstract

The ability of highly purified CD8+ T cells to mediate GVL activity and facilitate engraftment of allogeneic bone marrow cells was studied in the C57BL/Ka-->BALB/c mouse strain combination. Splenic CD8+ T cells were enriched by depletion of CD4+ T cells by "planning" or purified by positive selection by cell sorting. Although C57BL/Ka bone marrow cells reconstitute lethally irradiated BALB/c mice without severe GVHD, the addition of at least 1.0 x 10(6) donor spleen cells induced uniform acute lethal GVHD. Equivalent doses of spleen cells depleted of CD4+ T cells failed to induce lethal GVHD. Allogeneic bone marrow cells alone failed to mediate antitumor activity against the BCL1 B cell leukemia/lymphoma as compared with syngeneic bone marrow and spleen cell injections. Despite the inability to induce severe GVHD, CD4+ T cell-depleted allogeneic spleen cells prevented the progressive growth of the BCL1 tumor, and eliminated BCL1 idiotype-positive tumor cells in the blood. In order to determine whether CD8+ T cells can prevent tumor growth in the absence of other spleen cell subsets, such as NK cells, that are present in the CD4- populations, highly purified CD8+ T cells were obtained by positive selection using flow cytometry. The latter cells prevented the progressive growth of the tumor, and markedly reduced the level of tumor cells in the blood. Sorted CD8+ T cells facilitated the engraftment of allogeneic marrow cells in sublethally irradiated hosts. Thus, addition of highly purified CD8+ T cells to marrow cells provides GVL activity and facilitates engraftment without inducing severe GVHD in most recipients.

Entities:  

Mesh:

Year:  1995        PMID: 7652765     DOI: 10.1097/00007890-199508270-00010

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse.

Authors:  Benny J Chen; Divino Deoliveira; Xiuyu Cui; Ngocdiep T Le; Jessica Son; John F Whitesides; Nelson J Chao
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.

Authors:  Antonia M S Müller; Mareike Florek; Holbrook E K Kohrt; Natascha J Küpper; Alexander Filatenkov; Jessica A Linderman; Husein Hadeiba; Robert S Negrin; Judith A Shizuru
Journal:  J Immunol       Date:  2016-10-10       Impact factor: 5.422

3.  Prevention of graft rejection by donor type II CD8(+) T cells (Tc2 cells) is not sufficient to improve engraftment in fetal transplantation.

Authors:  Jeng-Chang Chen; Ming-Ling Chang; Hanmin Lee; Marcus O Muench
Journal:  Fetal Diagn Ther       Date:  2005 Jan-Feb       Impact factor: 2.587

Review 4.  Murine models of transplantation tolerance through mixed chimerism: advances and roadblocks.

Authors:  B Mahr; T Wekerle
Journal:  Clin Exp Immunol       Date:  2017-05-22       Impact factor: 4.330

Review 5.  The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

6.  Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.

Authors:  D Zeng; D Lewis; S Dejbakhsh-Jones; F Lan; M García-Ojeda; R Sibley; S Strober
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

7.  Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.

Authors:  Marilène Binsfeld; Yves Beguin; Ludovic Belle; Eléonore Otjacques; Muriel Hannon; Alexandra Briquet; Roy Heusschen; Pierre Drion; Jenny Zilberberg; Bjarne Bogen; Frédéric Baron; Jo Caers
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

8.  Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation.

Authors:  Asha B Pillai; Tracy I George; Suparna Dutt; Pearline Teo; Samuel Strober
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

9.  Bone marrow T cells are superior to splenic T cells to induce chimeric conversion after non-myeloablative bone marrow transplantation.

Authors:  Hyun-Sil Park; Seok-Goo Cho; Min-Jung Park; So-Youn Min; Hong-Seok Chang; Hee-Je Kim; Seok Lee; Chang-Ki Min; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim; Ho-Youn Kim
Journal:  Korean J Intern Med       Date:  2009-08-26       Impact factor: 3.165

10.  Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib.

Authors:  Naoko Okiyama; Yasuko Furumoto; Vadim A Villarroel; Jay T Linton; Wanxia L Tsai; Jan Gutermuth; Kamran Ghoreschi; Massimo Gadina; John J O'Shea; Stephen I Katz
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.